News

The U.S. Food and Drug Administration (FDA) has lifted its full clinical hold on IkT-148009, Inhibikase Therapeutics’ investigational oral therapy for Parkinson’s disease. The agency had placed a hold on all clinical trials of IkT-158009 in December, just a few months after Inhibikase had begun dosing Parkinson’s patients in a …

Annovis Bio anticipates an interim data analysis from a Phase 3 trial of its therapeutic candidate buntanetap in people with early-stage Parkinson’s disease will be possible by mid-year, based on current trial enrollment. By then, there will likely be enough patients who’ll have received at least two months…

The PD GENEration study is halfway to its goal of providing free genetic testing and counseling to 15,000 people with Parkinson’s disease, with 7,500 patients included in the effort to date. “Ensuring that the entire Parkinson’s community — including the 90,000 individuals expected to receive a PD [Parkinson’s…

A cognitive-motor training program featuring a video game platform that promotes exercise is feasible for people with Parkinson’s disease to use, a new study demonstrates. Patients using the program along with standard rehabilitation showed comparable and greater motor and cognitive improvements relative to those on standard rehabilitation alone. These preliminary…

Treatment with stem cells engineered to produce a signaling protein called VEGF — which drives the growth of blood vessels — was found to lead to pain relief in a mouse model of Parkinson’s disease. Researchers say engineering stem cells for use in transplant “may potentiate the therapeutic efficacy”…

Taking part in a community-based exercise program appears to help relieve the motor symptoms of Parkinson’s disease, a review study suggests. Researchers also observed that older people and those engaging in these programs for longer periods may get the most benefit. The review study, “Effects and parameters of community-based…

People with REM sleep behavior disorder (RBD) — an early nonmotor symptom of Parkinson’s disease — were significantly more likely than others to wrongly think their sense of smell was normal when olfactory deficits were evident, a small study found. Parkinson’s patients with RBD also had a diminished sense…

The C-reactive protein-to-albumin ratio (CAR), a measure of inflammation in the body that can be read from a routine blood test, may be linked to all-cause mortality in people with Parkinson’s disease, according to study of people in Japan. Data showed patients with the highest CAR were up to…

Treatment with evening primrose oil or EPO — made from the seeds of the flowering plant — was found to reduce brain inflammation and improve motor function in a rat model of Parkinson’s disease-like features, referred to as parkinsonism. A new study in Egypt found that the oil, which…

VectorY Therapeutics and Annogen have announced a new agreement to work toward developing vectorized antibody therapies for Parkinson’s disease and other neurological conditions. “We are delighted to work together with Annogen on novel tailored cell-specific promoters to enhance VectorY’s transformative AAV-vectorized antibody platform and its potential to…